KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Gains from Investment Securities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Gains from Investment Securities for 13 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 261.59% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.1 million, a 261.59% increase, with the full-year FY2025 number at $11.1 million, up 261.59% from a year prior.
  • Gains from Investment Securities was $11.1 million for Q4 2025 at Xenon Pharmaceuticals, down from $11.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.7 million in Q2 2025 to a low of -$518000.0 in Q1 2025.
  • A 5-year average of $5.8 million and a median of $5.8 million in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 1033.4% in 2022, then plummeted 2839.15% in 2025.
  • Xenon Pharmaceuticals' Gains from Investment Securities stood at $5.6 million in 2021, then rose by 26.24% to $7.1 million in 2022, then grew by 24.96% to $8.9 million in 2023, then plummeted by 65.57% to $3.1 million in 2024, then soared by 261.59% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Gains from Investment Securities are $11.1 million (Q4 2025), $11.7 million (Q2 2025), and -$518000.0 (Q1 2025).